Prognostic significance of MRI contrast enhancement in newly diagnosed glioblastoma, IDH-wildtype according to WHO 2021 classification

Background and objectives Contrast enhancement in glioblastoma, IDH -wildtype is common but not systematic. In the era of the WHO 2021 Classification of CNS Tumors, the prognostic impact of a contrast enhancement and the pattern of contrast enhancement is not clearly elucidated. Methods We performed...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2024-09, Vol.169 (2), p.445-455
Main Authors: Roux, Alexandre, Elia, Angela, Hudelist, Benoit, Benzakoun, Joseph, Dezamis, Edouard, Parraga, Eduardo, Moiraghi, Alessandro, Simboli, Giorgia Antonia, Chretien, Fabrice, Oppenheim, Catherine, Zanello, Marc, Pallud, Johan
Format: Article
Language:English
Subjects:
Case Study
Classification
Glioblastoma
Glioma
Medical prognosis
Medicine
Medicine & Public Health
Neurology
Neurosurgery
Oncology
Survival
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and objectives Contrast enhancement in glioblastoma, IDH -wildtype is common but not systematic. In the era of the WHO 2021 Classification of CNS Tumors, the prognostic impact of a contrast enhancement and the pattern of contrast enhancement is not clearly elucidated. Methods We performed an observational, retrospective, single-centre cohort study at a tertiary neurosurgical oncology centre (January 2006 - December 2022). We screened adult patients with a newly-diagnosed glioblastoma, IDH -wildtype in order to assess the prognosis role of the contrast enhancement and the pattern of contrast enhancement. Results We included 1149 glioblastomas, IDH -wildtype: 26 (2.3%) had a no contrast enhancement, 45 (4.0%) had a faint and patchy contrast enhancement, 118 (10.5%) had a nodular contrast enhancement, and 960 (85.5%) had a ring-like contrast enhancement. Overall survival was longer in non-contrast enhanced glioblastomas (26.7 months) than in contrast enhanced glioblastomas (10.9 months) ( p  
ISSN:0167-594X
1573-7373
1573-7373
DOI:10.1007/s11060-024-04747-7